The estimated Net Worth of Douglas Hillman is at least $14.4 Thousand dollars as of 27 June 2012. Douglas Hillman owns over 1,820 units of AIM ImmunoTech Inc stock worth over $14,372 and over the last 17 years Douglas sold AIM stock worth over $0.
Douglas has made over 9 trades of the AIM ImmunoTech Inc stock since 2008, according to the Form 4 filled with the SEC. Most recently Douglas bought 1,820 units of AIM stock worth $6,370 on 27 June 2012.
The largest trade Douglas's ever made was buying 5,000 units of AIM ImmunoTech Inc stock on 16 December 2010 worth over $13,250. On average, Douglas trades about 2,798 units every 117 days since 2008. As of 27 June 2012 Douglas still owns at least 46,377 units of AIM ImmunoTech Inc stock.
You can see the complete history of Douglas Hillman stock trades at the bottom of the page.
Douglas's mailing address filed with the SEC is 1212 N Hercules Ave, Clearwater, FL 33765, USA.
Over the last 20 years, insiders at AIM ImmunoTech Inc have traded over $15,026,013 worth of AIM ImmunoTech Inc stock and bought 898,126 units worth $656,210 . The most active insiders traders include Thomas K Equels, J Mervyn Nabors, and Commercial Bank First. On average, AIM ImmunoTech Inc executives and independent directors trade stock every 125 days with the average trade being worth of $16,943. The most recent stock trade was executed by Thomas K Equels on 6 May 2024, trading 61,729 units of AIM stock currently worth $25,309.
aim immunotech inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency disorders in the united states. the company's products include alferon n injection, an injectable formulation of natural alpha interferon to treat a category of genital warts, a sexually transmitted disease; and ampligen, a drug of macromolecular ribonucleic acid molecule for the treatment of chronic fatigue syndrome. it is also developing ampligen for the treatment of hepatitis b and hiv, as well as patients with renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, urothelial, prostate, and pancreatic cancer. aim immunotech inc. has research agreement with the japanese national institute of infectious diseases and shionogi & co., ltd. to test its drug ampligen as an adjuvant therapy for covid-19, the new coronavirus infectious disease caused by sars-cov-2. the company was formerly known as
AIM ImmunoTech Inc executives and other stock owners filed with the SEC include: